Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 12/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20079386 | 0.83 | PGR (0.54) | POLBPGRMAOBDAOCYP3A4 | |
| SCHEMBL9995469 | 0.79 | DAO (0.60) | POLBPGRMAOBDAOCYP3A4 | |
| SCHEMBL22972503 | 0.77 | PDE3B (0.49) | PGRMAOBDAOPDE3BPDE3A | |
| SCHEMBL20079380 | 0.75 | DAO (0.58) | POLBPGRMAOBDAOCYP3A4 | |
| SCHEMBL25352500 | 0.72 | PGR (0.46) | POLBPGRMAOBCYP3A4CYP2B6 | |
| SCHEMBL29703148 | 0.72 | PGR (0.46) | POLBPGRMAOBCYP3A4CYP2B6 | |
| SCHEMBL20656323 | 0.70 | PGR (0.50) | POLBPGRMAOBDAOALDH1A1 | |
| SCHEMBL25352403 | 0.69 | PGR (0.41) | POLBPGRMAOBDAOCYP3A4 | |
| SCHEMBL20079382 | 0.69 | PGR (0.55) | POLBPGRMAOBDAOCYP3A4 | |
| SCHEMBL20079384 | 0.69 | PGR (0.58) | POLBPGRMAOBDAOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664036-B1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | PFIZER INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7776885-B2 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1664036-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005021539-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | HTR4, GPR4, HTR5A | POLB 4732/4885PGR 2397/4885MAOB 1273/4885 |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | HTR4, GPR4, HTR5A | POLB 4732/4885PGR 2397/4885MAOB 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.